Answers are grounded in this paper and cite their sources.
Delayed lactogenesis II (DLII), usually defined as perceived onset of copious secretion after 72 h postpartum, affects about 30% of mothers and is linked to earlier breastfeeding cessation. Its frequent risk factors—maternal obesity, diabetes in pregnancy, hypertensive disorders of pregnancy (HDP), and caesarean delivery—can also affect early milk removal and onset ascertainment. This narrative review, drawing on PubMed/MEDLINE searches and citation tracking, assessed whether biological, care-related, and measurement explanations are distinguishable, weighing design, outcome definition, and documented early care. A biological contribution is probable in type 1 diabetes, in which biomarker-defined delay has been replicated, but remains emerging in type 2 diabetes and gestational diabetes, and neonatal care may confound all three. In obesity, care-related and biological contributions are both emerging; the only mediation analysis measured early care, breastfeeding difficulties, and onset concurrently. After caesarean birth, two randomised trials of early essential newborn care bundles advanced mean reported onset by about 9 h, with uncertain effect on DLII incidence. HDP associations are heterogeneous, largely unadjusted, and mechanistically untested. Onset is mostly self-reported. Protecting early milk removal, as guidelines recommend, is warranted alongside indicated maternal and neonatal treatment; studies pairing milk biomarkers with recorded care should define the biological component.
No takes yet. Share an insight, caveat, or question.
Mogos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: